A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
HX008 is a humanized monoclonal antibody targeting PD-1 on the T cell surface, restores T
cell activity, thus enhancing immune response, and has the potential to treat various types
of tumors. In this study, the tolerance and safety of HX008 in patients with advanced solid
tumors will be evaluated.